Hester Biosciences (BOM:524669) Other Current Payables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524669 Hester Biosciences Ltd BOM:524669
72 GF Score
Price ₹2,452.85
GF Value ₹1,870.35
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hester Biosciences Other Current Payables?

Hester Biosciences BOM:524669 -1.21% 72 Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:524669 with a GF Score™ of 72/100 and a GF Value™ of ₹1,870.35 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hester Biosciences's Other Current Payables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Hester Biosciences's quarterly Other Current Payables increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹169 Mil) but then declined from Mar. 2026 (₹169 Mil) to Jun. 2026 (₹0 Mil).

Hester Biosciences's annual Other Current Payables declined from Mar. 2024 (₹132 Mil) to Mar. 2025 (₹120 Mil) but then increased from Mar. 2025 (₹120 Mil) to Mar. 2026 (₹169 Mil).

Hester Biosciences Other Current Payables Related Terms

Hester Biosciences Other Current Payables Historical Data

* Premium members only.

The historical data trend for Hester Biosciences's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hester Biosciences Other Current Payables Chart

Hester Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 149.40 184.10 132.06 119.53 168.69

Hester Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 168.69 0.00
BOM:524669
72GF Score
Hester Biosciences Ltd BOM:524669
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hester Biosciences Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Hester Biosciences (BOM:524669) has a Other Current Payables of ₹0 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hester Biosciences and its competitors.
Is Hester Biosciences' Other Current Payables too high?
Hester Biosciences' current Other Current Payables is ₹0 Mil. Overall, Hester Biosciences has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Other Current Payables compare to ZTS?
Hester Biosciences' Other Current Payables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hester Biosciences and its competitors. Hester Biosciences's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,870.35, compared to a current price of ₹2,452.85 — trading 31.1% above its estimated fair value. The current Other Current Payables is ₹0 Mil. Hester Biosciences' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hester Biosciences (BOM:524669) Overvalued in 2026?

Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued. The current stock price of ₹2,452.85 is trading 31.1% above its estimated GF Value™ of ₹1,870.35. GuruFocus considers Hester Biosciences to be Significantly Overvalued.

Key valuation signals for BOM:524669:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹1,870.35 vs. price of ₹2,452.85 (31.1% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hester Biosciences Business Description

Other Exchanges HESTERBIO:India
Address Village Meda - Adraj, Taluka Kadi, District Mehsana, Mehsana, GJ, IND, 384441
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
72GF Score

Get the complete analysis for BOM:524669

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,452.85
Price
₹1,870.35
GF Value